RxDoctor Payments Data

Courtney Hood

Nurse Practitioner · Muscle Shoals, ALNPI 1972894442

Payments from drug & device makers

$875in general payments, 2019–2025

Across 41 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$375
  • AstraZeneca$126
  • Novo Nordisk$98
  • Lilly USA, LLC$75
  • Genentech USA, Inc.$60
  • Alnylam Pharmaceuticals Inc.$56
  • plus $85 from 5 others

What the payments were for

  • Food & beverage$875100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$875 in reported general payments places this provider in the 70th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$14,810
Medicare patients
79
Services billed
570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$27,146
MounjaroTirzepatide16$19,906
JanumetSitagliptin Phos/Metformin Hcl13$7,379
Bupropion XlBupropion Hcl29$350
Methylprednisolone42$300
Cefdinir15$283
Rosuvastatin Calcium22$270
Levothyroxine Sodium21$252
Metformin Hcl ErMetformin Hcl25$251
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide27$227
Pantoprazole Sodium22$198
Fluoxetine Hcl15$140
Omeprazole12$120
Azithromycin28$113
Metformin Hcl34$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$98$27,14628 claims
Lilly USA, LLCMounjaro$75$19,90616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Muscle Shoals

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →